Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 7/20 | 0.40 |
| ▸ | CES1 | P23141 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10536748 | 0.96 | CES2 (0.48) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL12098894 | 0.89 | CES2 (0.46) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL2476072 | 0.89 | CES2 (0.46) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL27372386 | 0.81 | CES2 (0.52) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL27534637 | 0.79 | CES2 (0.48) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL9285330 | 0.78 | CES2 (0.44) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL225787 | 0.77 | GGPS1 (0.45) | CES2LPAR1LPAR3GGPS1FDPS | |
| SCHEMBL6058687 | 0.77 | GGPS1 (0.45) | CES2LPAR1LPAR3GGPS1FDPS | |
| SCHEMBL25341533 | 0.77 | CES2 (0.55) | CES2LPAR1LPAR3FAAHCES1 | |
| SCHEMBL30451394 | 0.77 | CES2 (0.55) | CES2LPAR1LPAR3FAAHCES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232917-B2 | Cyclic fluorine compounds, polymerizable fluoromonomers, fluoropolymers, and resist materials containing the fluoropolymers and method for pattern formation | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-06-19 | — | — | US | disclosed |
| US-20060270864-A1 | Cyclic fluorine compounds, polymerizable fluoromonomers, fluoropolymers, and resist materials containing the fluoropolymers and method for pattern formation | CENTRAL GLASS COMPANY, LIMITED (JP) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270864-A1 | Cyclic fluorine compounds, polymerizable fluoromonomers, fluoropolymers, and resist materials containing the fluoropolymers and method for pattern formation | AFF1, FPR1, AFF4 | CES2 3845/4885LPAR1 840/4885LPAR3 541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.